OPR - Delayed Quote • USD AUTL Jun 2024 10.000 call (AUTL240621C00010000) Follow 0.2400 0.0000 (0.00%) At close: April 4 at 12:47 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for AUTL240621C00010000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: AUTL Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) Autolus Therapeutics Announces Changes to its Board of Directors Q4 2023 BioNTech SE Earnings Call Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations Q4 2023 Autolus Therapeutics PLC Earnings Call Autolus Therapeutics PLC Reports Full Year 2023 Financial Results Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
